Overview

Motif Neurotech addresses psychiatric disease, pursuing a distinct market within a neurotech field largely focused on paralysis. The company develops minimally invasive neurostimulation approaches for major depressive disorder that is treatment-resistant to conventional medications. Founded in 2022, Motif targets an unmet need in psychiatry.

Market Opportunity

Chief executive and co-founder Jacob Robinson has framed the market as a ratio: for every person with a spinal cord injury, there are 10 people with major depressive disorder who are not responding to drugs, which he called “an absolutely massive market.” This ratio underscores the enormous patient population available for psychiatric neurotech interventions compared to motor BCIs focusing on paralysis alone. Treatment-resistant depression affects roughly a third of the estimated 280 million people living with major depressive disorder worldwide.

Clinical Approach

Motif’s DOT implant is about 9 millimetres wide, battery-free and powered wirelessly by an external wearable. It sits between the skull and the dura, is placed in an outpatient procedure of about 20 minutes, and stimulates the dorsolateral prefrontal cortex, the region targeted by transcranial magnetic stimulation. On 27 April 2026 the FDA approved an investigational device exemption for the RESONATE early feasibility study in treatment-resistant depression, planned across up to eight institutions, and on 30 April MintNeuro announced a multi-year agreement to supply its chips.

Competitive Positioning

While most prominent BCI companies pursue motor control and communication, Motif’s focus on psychiatric applications represents an underexplored domain with distinct regulatory pathways and reimbursement models. The larger addressable patient population and established neurostimulation precedent (through deep brain stimulation) position psychiatric neurotech as an alternative pathway to commercialization.